Contact Us | News |  Site Map

Aridis Pharmaceuticals  © 2010   Le3 Web Designs

Privacy Policy

Strategic Approach

Our products target infectious diseases that have a significant impact on life expectancy and are selected based on their readiness to advance through clinical development.

Aridis’ therapeutic products drug candidates include gallium nitrate (PanaecinTM) and a human monoclonal antibody (AerucinTM), both effective against Pseudomonas aeruginosa, which chronically infects the lungs of cystic fibrosis and is commonly found in the lungs of non-CF brochiectasis, chronic obstructive pulmonary diseases (COPD) and ventilators assisted pneumonia (VAP) patients. Combining these potent therapies with targeted delivery in the form of inhalable formulations will fundamentally advance drug treatment beyond the limitations of chronic antibiotic use.